Dr. Alan List, MD
Hematologist / Oncologist
(813) 972-8400
About Dr. Alan List, MD
Dr. Alan List, MD is a Hematology-Oncology physician practicing at a clinic in Tampa, FL, dedicated to providing high-quality, comprehensive, and patient-centered care. He is registered with The Florida Board of Medicine and practices under the Florida Statutes, Title XXXII, Chapter 458 (Medical Practice). He specializes in diagnosing and treating a wide range of cancers and blood disorders, employing chemotherapy, immunotherapy, and other advanced therapies while prioritizing patient well-being and managing treatment side effects. He serves all ages, but is not currently accepting new patients. Please call (813) 972-8400 to inquire about waitlists or future openings.
Dr. Alan List, MD is a hematologist in Tampa, FL, affiliated with Moffitt Cancer Center Magnolia Campus. He completed rigorous medical training from recognized institutions, and further specialized through fellowship training in Hematology at Vanderbilt University Medical Center in Nashville, TN (graduated 1986). He is Board Certified in Hematology, Internal Medicine, and Medical Oncology by the American Board of Internal Medicine. Dr. List and his colleagues are recognized for their contributions to understanding the biology and investigating novel therapeutics for AML and MDS. He is the president and CEO of Moffitt Cancer Center and a senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program. While Dr. List is not accepting new patients, he provides consultations primarily in English.
Hemato-Oncologic Conditions Addressed
Dr. Alan List addresses a wide range of Hemato-oncologic health concerns, including:
- Nodular Lymphoma: Nodular lymphoma is a type of cancer that starts in the lymph nodes.
- Basal Cell Carcinoma: Basal cell carcinoma is a type of skin cancer that typically grows slowly and rarely spreads.
- Hemophilia: Hemophilia is a bleeding disorder where your blood doesn't clot properly, leading to prolonged bleeding.
- Lymphosarcoma: Lymphosarcoma is a type of cancer that affects the lymphatic system.
- Leukemia: Leukemia involves the abnormal growth of immature blood cells, which can spread to other parts of the body.
- Chronic Lymphocytic Leukemia: CLL is a slow-growing blood cancer affecting white blood cells called lymphocytes.
- Esophageal Cancer: Esophageal cancer is a type of cancer that starts in the esophagus, the tube that carries food from your mouth to your stomach.
- Venous Embolism and Thrombosis: Venous blood clots can form in your veins, sometimes leading to blockages.
- Marginal Zone Lymphoma: Marginal zone lymphoma is a type of cancer that affects the lymphatic system.
- Merkel Cell Carcinoma: This uncommon type of skin cancer, called Merkel cell carcinoma, often develops on sun-exposed areas of the body and can spread quickly if left untreated.
- Central Nervous System Lymphoma: Central nervous system lymphoma is a lymphoma that develops in the tissues of the brain or spinal cord.
- Purpura: Purpura is a condition characterized by reddish or purplish spots on the skin caused by bleeding under the skin's surface.
Please note: This list highlights some common health concerns that Dr. Alan List addresses and is for informational purposes only; it does not constitute medical advice. The range of conditions a Hematology-Oncology manages is broad, and this list is not exhaustive. For a comprehensive understanding of how he can assist with your Patient's specific health needs or to discuss any particular symptoms, it's always best to schedule a consultation. Accurate diagnosis and personalized treatment plans are developed based on individual patient evaluations.
Hemato-Oncologic Services Provided
Dr. Alan List offers a range of services to support your Patient's health and well-being, such as:
- Anemia and Iron Deficiency Screening: This service helps identify and treat anemia and iron deficiency.
- Bone Marrow Transplant: Our bone marrow transplant service provides comprehensive care for patients undergoing a bone marrow transplant.
- Cancer Screening: Cancer screenings aim to reduce cancer deaths by finding cancers early, when treatment is most effective.
- Erythropoietin Test: This test measures the level of erythropoietin in your blood to help understand your red blood cell production.
- Oral Cancer Screening: This service provides screenings to detect oral cancer in its early stages.
- Skin Screenings: This service provides comprehensive skin examinations to detect and prevent skin cancer.
- Cancer Immunotherapy: Cancer immunotherapy involves medications or other therapies that stimulate your immune response against the cancer.
Please note: This list highlights some of the key services that may be offered by Dr. Alan List. Service availability can change and not all services listed may be appropriate or offered to every patient. The scope of services provided by a Hematology-Oncology can vary. For a comprehensive understanding of all available services or to discuss your Patient's specific healthcare needs, it's always best to schedule a consultation. Some specialized procedures or advanced diagnostic tests may require referral to a subspecialist.
All medical services are provided in accordance with the standard scope of practice for Hematology-Oncology in Florida and adhere to the ethical and professional guidelines set forth by The Florida Board of Medicine.
- Primary Location:
Practice
12902 Usf Magnolia Dr, Tampa, FL, 33612
Phone: (813) 972-8400
View on Map
- Fellow, Vanderbilt University Medical Center, Nashville, TN, - Hematology|Vanderbilt University Hospital (Fellowship Hospital) - 1986
- American Board of Internal Medicine (Hematology)
- American Board of Internal Medicine (Internal Medicine)
- American Board of Internal Medicine (Medical Oncology)
- Moffitt Cancer Center Magnolia Campus
- A Model for Prediction ofFLT3-ITD andNPM1(withoutFLT3-ITD) Positivity in Patients with Newly Diagnosed Acute Myeloid Leukaemia, 2013-07-06
- Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide, 2016-08-18
- Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide, 2012-03-05
- Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes, 2018-01-23
- S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes, 2019-02-08
- Outcomes After Induction Chemotherapy in Patients With Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome, 2010-11-08
- Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia, 2021-07-12
- TP53andMDM2single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes, 2015-09-25
- Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis, 2019-04-03
- Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia, 2019-10-21
- A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS), 2019-03-30
- Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndromes, 2013-06-21
- Erythropoietin Receptor Signaling Is Membrane Raft Dependent, 2012-04-03
- Recurrent genetic defects on chromosome 5q in myeloid neoplasms, 2016-12-23
- Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q), 2017-06-26
- Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors, 2014-12-03
- Prognostic Significance of MYC Oncoprotein Expression on Survival Outcome in Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC), 2019-07-18
- Sequential phase II Southwest Oncology Group studies (S0012 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with cyclosporine, in older patients with previously untreated acute myeloid leukemia (AML), 2009-10-11
- Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium, 2014-11-19
- Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients, 2020-07-13
- Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots, 2016-05-26
- Association of immunophenotype with expression of topoisomerase II a and u00df in adult acute myeloid leukemia, 2020-03-26
- Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes, 2011-02-21
- Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML), 2020-07-29
- Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41, 2016-04-06
- The Prognostic Significance ofIRF8Transcripts in Adult Patients with Acute Myeloid Leukemia, 2013-08-14
- Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutatedRUNX1versus acute myeloid leukemia with myelodysplasia-related changes with mutatedRUNX1, 2020-02-24
- Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening, 2009-05-05
- JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth, 2012-11-15
- SWOG0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Relapsed Acute Myeloid Leukaemia, 2014-07-18
- Diagnostic Testing, Treatment, Cost of Care, and Survival among Registered and Non-registered Patients with Myelodysplastic Syndromes, 2011-08-17
- Loss of function of DOCK4 in myelodysplastic syndromes stem cells is restored by inhibitors of DOCK4 signaling networks, 2019-07-15
- Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation, 2011-12-23
- Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes, 2011-01-10
- Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancies, 2013-08-06
- Naive T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency, 2012-10-17
- Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?, 2015-08-11
- Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents, 2015-12-22
- Expansion of Effector Memory Regulatory T-cells Represents A Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome, 2012-08-08
- Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes, 2022-08-08
- Telomere length in myelodysplastic syndromes, 2011-06-03
- SF3B1Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes, 2020-01-10
- Underreporting of Myeloid Malignancies by United States Cancer Registries, 2012-01-11
- AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report, 2020-08-12
- A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML), 2016-02-08
- The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q), 2018-09-21
- TP53Mutation Status Divides Myelodysplastic Syndromes with Complex Karyotypes into Distinct Prognostic Subgroups, 2019-01-11
- Effects of azacitidine compared with conventional care regimens in elderly (=75 years) patients with higher-risk myelodysplastic syndromes?, 2010-05-06
Frequently Asked Questions
Here are answers to some common questions about care with Dr. Alan List:
- What is a Hematologist/Oncologist?
- A hematologist/oncologist is a doctor specializing in both the study and treatment of blood disorders and cancers. They diagnose and treat various blood cancers, solid tumors, and non-cancerous blood disorders. Their expertise lies in both hematology and oncology.
- What should I expect during my first visit with Dr. Alan List?
- Your first visit with Dr. List will be a comprehensive consultation. We will review your medical history, conduct a physical exam, and discuss your diagnosis and potential treatment options in detail. Please bring all prior medical records, imaging reports, and pathology slides to ensure a thorough evaluation.
- Does Dr. Alan List accept my insurance?
- Dr. List's practice accepts many insurance plans. However, cancer and hematology care can be complex. Please contact our financial counselors or your insurance provider directly to verify coverage for your specific treatments.
- I have a history of blood clots. How is that managed during cancer treatment?
- Cancer and its treatments can increase the risk of blood clots. Dr. List is an expert in managing this risk, often by prescribing anticoagulants and closely monitoring patients.
- How does Dr. Alan List help manage treatment side effects?
- Dr. List prioritizes managing treatment side effects. He proactively prescribes medications for nausea and pain, provides nutritional support, closely monitors blood counts, and offers resources to help patients cope with fatigue and other issues.
- What is the typical treatment for lymphoma?
- Treatment for lymphoma varies greatly depending on the specific type and stage of the disease. Common approaches often include combinations of chemotherapy and targeted immunotherapies, like rituximab, and sometimes radiation therapy for localized disease. Your doctor will discuss the best treatment plan tailored to your individual situation.
- What is a bone marrow biopsy and why do I need one?
- A bone marrow biopsy is a crucial diagnostic procedure where a small sample of bone marrow is taken, typically from the back of the hip bone. It allows examination of the cells under a microscope, helping to diagnose conditions like leukemia, lymphoma, and other blood disorders.
- What is chemotherapy and how is it given?
- Chemotherapy is a cancer treatment that uses powerful drugs to kill fast-growing cancer cells. It can be given intravenously (IV) through a port or vein, or sometimes as oral pills. The specific method depends on the type of cancer and the patient's needs.
